 The study will be a double-blinded, placebo-controlled randomized study. The recruited patients would have had an established diagnosis of cardiomyopathy as documented by the history, examination and characteristic echocardiographic ECG findings. The patients would also have had a CMR scan demonstrating late gadolinium hyperenhancement previously. These patients will have been established on maximally tolerated doses of standard drugs used in the treatment of cardiomyopathy including ACE inhibitors and beta blockers as appropriate and the doses of these drugs would have remained unchanged in the 2 months preceding enrollment to the trial. Patients would be randomized to receive a maximal dose of 50mg eplerenone or placebo. The study dose of Eplerenone to be used will be initially 25mg once daily one tablet. After 4 weeks, provided it has been well tolerated with no problems the dose will be increased to the usual maintenance dose of 50mg once daily two tablets. For patients receiving placebo, the number of tablets received will match the Eplerenone group at the same time points. 